On November 3, 2023 Verismo Therapeutics, a clinical-stage CAR-T company developing novel KIR-CAR platform technology reported that it will be presenting at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting (SITC 2023), to be held in San Diego and virtually November 1-5, 2023 (Press release, Verismo Therapeutics, NOV 3, 2023, View Source [SID1234636926]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation Details
Title: Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma
Abstract Number: 321
Date and Time: Friday, November 3rd: 12:00-1:30 p.m. and 5:10-6:40 p.m.
Presenting Authors: Dr. Jun Xu, PhD & Dr. Laura Johnson, PhD
Description: We conducted in vivo potency studies to assess the impact of the engineered T cell dose of the first mesothelin (MSLN)-specific KIR-CAR T cell therapy (SynKIRTM-110) in an NSG mouse xenograft model of human mesothelioma. Our data demonstrate for the first time that anti-tumor efficacy of SynKIRTM-110 is dose-dependent with greater potency compared with MSLN-41BBz CAR T cells previously evaluated in the clinic. This enhanced potency of SynKIRTM-110 was observed both at the primary tumor site and metastatic sites as demonstrated by histopathologic analysis. This increased potency did not impact any serum markers of toxicity, which remained the same regardless of CAR/KIR-CAR treatments. This data supports further clinical development of SynKIRTM-110 in patients with advanced solid tumors. SynKIRTM-110 is currently being investigated in a Phase I clinical trial STAR-101 (NCT05568680).
About the KIR-CAR Platform
The KIR-CAR platform is a dual-chain CAR T cell therapy and has been shown in preclinical animal models to be capable of maintaining antitumor T cell activity even in challenging solid tumor environments. DAP12 acts as a novel costimulatory molecule for T cells using additional T cell stimulating pathways, further sustaining chimeric receptor expression and improving KIR-CAR T cell functional persistence. This continued T cell function and persistence can lead to ongoing regression of solid tumors in preclinical models, including those resistant to traditional CAR T cell therapies. The KIR-CAR platform is being investigated in combination with additional emerging technologies.